Solide Tumoren - Skelettsystem - Ewing-Sarkom - Weiterführende Informationen

Leitlinien

leitlinien.net; Nr.: 025/006; 2009 aktualisiert; www.awmf.org/uploads/tx_szleitlinien/
025-006.pdf

inderkrebsinfo: http://www.kinderkrebsinfo.de/e1676/e9032/e1758/e78199/index_ger.html

Studien

EWING 2008-Studie, Leiter: Prof. Dr. med. H. Jürgens, Univ.-Kinderklinik, Klinik für Pädiatr. Hämatologie u. Onkologie, Albert-Schweitzer-Str. 33, 48129 Münster; Tel. (02 51) 8 35 77 49. http://klinikum.uni-muenster.de/index.php?id=4810

Literatur

• Balamuth NJ, Womer RB: Ewings’s sarcoma. The Lancet Oncology 2010; 11: 184–92

• Bestic et al: Use of FDG PET in staging, restaging, and assessment of therapy response in Ewing sarcoma. Radiographics 2009; 29: 1487 #500

• Bielack SS, Carrle D: State-of-the-art approach in selective curable tumors: bone sarcoma. Ann Oncol 2008; 19 (suppl 7): vii 155–60

• Bielack SS et al: Bone tumors in adolescents and young adults. Curr Treat Options Oncol 2008; 9: 67–80

• Caudill JS, Arndt CA: Diagnosis and management of bone malignancy in adolescence. Adolesc Med State Art Rev 2007; 18: 62–78

• Heare T et al: Bone tumors: osteosarcoma and Ewing’s sarcoma. Curr Opin Pediatr 2009; 21: 365–72

• Leavey PJ, Collier AB: Ewing sarcoma: prognostic criteria, outcomes and future treatment Expert Rev Anticancer Ther 2008; 8: 617–24

• Ludwig JA: Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future. Curr Opin Oncol 2008; 20: 412–8

• Olmos D et al: Targeting the insulin-like growth factor 1 receptor in ewing’s sarcoma: reality and expectations. Sarcoma 2010; published online doi:10.1155/2011/402508

• Ordóñez JL et al: Advances in Ewing‘s sarcoma research: where are we now and what lies ahead? Cancer Res 2009; 69: 7140–50